Corporate | 2 March 2009 07:43
WILEX AG / Capital Increase
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Munich, 02 March 2009: The Munich-based biopharmaceutical company WILEX AG
(ISIN DE0006614720; Frankfurt Stock Exchange; Prime Standard) reports the
closing of the transaction with the global biopharmaceutical company UCB,
Brussels/Belgium, announced in the adhoc and press releases dated 8/9
January 2009. The capital increase through a contribution in kind, as part
of the strategic alliance, has been recorded in the company's Commercial
Register.
Professor Olaf G. Wilhelm, Chairman of the Executive Management Board of
WILEX AG, commented: 'The prompt closing of this transaction enables us to
continue the development of the preclinical oncology portfolio we acquired
from UCB. It is an important step to achieve our next milestones.'
The Executive Management Board of WILEX AG had resolved on 18 February 2009
with the approval of the Supervisory Board to increase the Company's share
capital from EUR 11,962,754.00 by EUR 1,818,181.00 to EUR 13,780,935.00 by
issuing 1,818,181 new shares. This capital increase was executed using
authorised capital in return for a contribution in kind and is subject to
the exclusion of all previous WILEX shareholders' statutory subscription
rights.
The new shares, which are entitled to participate in profits effective from
1 December 2008, were subscribed in full by UCB. Its in-kind contribution
to WILEX comprises all shares in a wholly-owned subsidiary. The acquired
company holds comprehensive rights to five preclinical oncology programmes
and has EUR 10 million in cash on hand.
The appropriate Commercial Register recorded the capital increase on 26
February 2009. Hence UCB now owns 13.19% of WILEX's shares.
WILEX will now apply to have 909,091 of the new shares (ISIN DE0006614720)
listed in the Regulated Market (Prime Standard). Provided Deutsche Börse AG
grants the Company's partial listing request, the remaining 909,090 new
shares (DE000A0XFV54) will be listed upon expiration of the contractually
stipulated lock-up period on 9 January 2011.
About WILEX AG:
WILEX AG is a biopharmaceutical company based in Munich and is listed at
the Frankfurt Stock Exchange at the Regulated Market / Prime Standard.
WILEX's mission is to develop drugs with a low side effect profile and
targeted treatment of different types of cancer as well as diagnostic
agents for specific detection of tumours. The Company's product candidates
are based on antibodies and small molecules. WILEX has an attractive
product pipeline which includes both drug and diagnostic candidates: The
substances RENCAREX(R) and REDECTANE(R) are currently undergoing a Phase
III registration trial. MESUPRON(R) is in a Phase II programme. Another
five programmes are in preclinical development. WILEX aims within a few
years to be able to finance its research and development programmes from
its operating cash flow. In order to achieve this goal, the Executive
Management Board pursues a commercialisation strategy for all products.
(Website: www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6)
Contact
Katja Arnold (CIRO)
WILEX AG
Grillparzerstr. 10
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors@wilex.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
02.03.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------